Canaccord Genuity analyst John Newman maintained a Buy rating on Atara Biotherapeutics (ATRA) yesterday and set a price target of $70.00. The company’s shares closed last Thursday at $9.15, close to its 52-week low of $4.52.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 12.7% and a 43.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $40.67 average price target, a 363.7% upside from current levels. In a report issued on April 23, Citigroup also upgraded the stock to Buy with a $14.00 price target.
See today’s analyst top recommended stocks >>
Based on Atara Biotherapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $78.5 million. In comparison, last year the company had a GAAP net loss of $80.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.